Evidence map›Paper›PMID 31185953›Full record

ArticleBMC cancer2019

Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.

Thasni Karedath, Ikhlak Ahmed, Wafa Al Ameri, Fatima M Al-Dasim, Simeon S Andrews, Samson Samuel, Iman K Al-Azwani, Yasmin Ali Mohamoud, Arash Rafii, Joel A Malek

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.International journal of molecular sciences · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Noncoding RNAs in tumor metastasis: molecular and clinical perspectives.Cellular and molecular life sciences : CMLS · 2021
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Thasni KaredathDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar.
Ikhlak AhmedDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar.
Wafa Al AmeriDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar.
Fatima M Al-DasimDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar.
Simeon S AndrewsDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar.
Samson SamuelDepartment of Pharmacology, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Iman K Al-AzwaniGenomics Core, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Yasmin Ali MohamoudGenomics Core, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Arash RafiiStem Cell and Microenvironment Laboratory, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Joel A MalekDepartment of Genetic Medicine, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, P.O. Box No, 24144, Doha, Qatar. jom2042@qatar-med.cornell.edu.ORCID http://orcid.org/0000-0002-1516-8477
Weill Cornell Medical College in Qatar · QA

Funding

Qatar Foundation/ Weill Cornell Medicine Qatar BMRP 1 - Pilot FY17
6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) that form through non-canonical backsplicing events of pre-mRNA transcripts are evolutionarily conserved and abundantly expressed across species. However, the functional relevance of circRNAs remains a topic of debate.

methodsWe identified one of the highly expressed circRNA (circANKRD12) in cancer cell lines and characterized it validated it by Sanger sequencing, Real-Time PCR. siRNA mediated silencing of the circular junction of circANKRD12 was followed by RNA Seq analysis of circANKRD12 silenced cells and control cells to identify the differentially regulated genes. A series of cell biology and molecular biology techniques (MTS assay, Migration analysis, 3D organotypic models, Real-Time PCR, Cell cycle analysis, Western blot analysis, and Seahorse Oxygen Consumption Rate analysis) were performed to elucidate the function, and underlying mechanisms involved in circANKRD12 silenced breast and ovarian cancer cells.

resultsIn this study, we identified and characterized a circular RNA derived from Exon 2 and Exon 8 of the ANKRD12 gene, termed here as circANKRD12. We show that this circRNA is abundantly expressed in breast and ovarian cancers. The circANKRD12 is RNase R resistant and predominantly localized in the cytoplasm in contrast to its source mRNA. We confirmed the expression of this circRNA across a variety of cancer cell lines and provided evidence for its functional relevance through downstream regulation of several tumor invasion genes. Silencing of circANKRD12 induces a strong phenotypic change by significantly regulating cell cycle, increasing invasion and migration and altering the metabolism in cancer cells. These results reveal the functional significance of circANKRD12 and provide evidence of a regulatory role for this circRNA in cancer progression.

conclusionsOur study demonstrates the functional relevance of circANKRD12 in various cancer cell types and, based on its expression pattern, has the potential to become a new clinical biomarker.

Indexed as

Gene SilencingBiomarkers, TumorBreastBreast NeoplasmsCell MovementCyclin D1ExonsG1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansLungLung NeoplasmsMCF-7 CellsNeoplasm InvasivenessNuclear ProteinsPhenotypeANKRD12 protein, humanBiomarkers, TumorCCND1 protein, humanCyclin D1Nuclear ProteinsRNA, CircularRNA, Small InterferingBreast cancerCancer invasionCircular RNAOCROXPHOSRNA-seqsiRNA

Identifiers

PMID31185953
PMCPMC6558796
OpenAlexW2951532207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.